University of Rochester

Rakuten Medical, Inc.

Incyte San Diego Inc.

Ortho-mcneil Pharmaceutical Corp.

Torsten R Wiemann

Stephen Dewhurst

Harris A Gelbard

Val S Goodfellow

Colin J Loweth

Catherine Tachdjian

Lyle W Spruce

Magnus Pfahl

Juan Manuel Betancort

Hussien A Al-Shamma

Andrea Fanjul

Lew Makings

Satheesh Babu Ravula

David P M Pleynet

Mohamed Boudjelal

David Pm Pleynet

Jason B Ibarra

Robert J Hoey

Colin Loweth

Disclosed herein are phthalocyanine dyes, and conjugates thereof, useful as fluorescent reporters for bioassays, for optical imaging and as therapeutic conjugates as the photosensitizing agents in light-based therapies including photoimmuno therapy (PIT). Certain phthalocyanine dyes disclosed herein are water soluble, and possess photophysical and photochemical profiles useful for use in imaging or therapy.

Phthalocyanine dye compounds, conjugates and methods of use thereof

Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. The compounds include substituted pyrrolo[2,3-b]pyridines having Formula IX  Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

Substituted pyrrolo[2,3-b]pyridines as MLK inhibitors

Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. The compounds include substituted pyrrolo [b]pyridines having Formula IX  Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors

Provided are compounds having an inhibitory effect on Mixed Lineage Kinases, having a structural Formula, Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

Provided are compounds having an inhibitory effect on kinases including Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders that comprise the inhibition of Mixed Lineage Kinases.

Bicyclic heteroaryl kinase inhibitors and methods of use

The invention relates to certain heterocyclic compounds useful for the treatment of cancer and other diseases, having the Formula (I): wherein:

Heterocyclic derivatives for the treatment of cancer and other proliferative diseases

The present invention relates to certain compounds of Formula (I) which can be useful in the treatment of diseases, such as, cancer, metabolic disorders, Type 2 Diabetes, dyslipidemia and/or hyperchloesterolemia: 

N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases

Growing community of inventors

Cardiff by the Sea, CA, United States of America

Torsten R Wiemann